Literature DB >> 18570182

Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.

Trine Ranheim1, Morten Mattingsdal, Jessica M Lindvall, Oystein L Holla, Knut Erik Berge, Mari Ann Kulseth, Trond P Leren.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum cholesterol. The possibility that PCSK9 also functions in other pathways needs to be addressed. We have transfected HepG2 cells with mutant D374Y-PCSK9 or control vector. Gene expression signatures were determined using the Affymetrix GeneChip technology, and the expression pattern of selected genes was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR). Data was normalized and analyzed using a model-based background adjustment for oligonucleotide expression arrays, then filtered based upon expression within treatments group, and subjected to moderated t-statistics. Five hundred twenty transcripts had altered expression levels between D374Y-PCSK9 and control vector. Among the 520 probes on our top list, 312 were found to have an assigned Gene Ontology (GO) term, and 96 were found in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Genome-wide expression profiling revealed that "steroid biosynthesis," "sterol metabolism," and "cholesterol biosynthsis" were affected by D374Y-PCSK9. Also, the GO biological process terms "response to stresss," "response to virus," "response to unfolded protein," and "immune response" were influenced by D374Y-PCSK9. Our results suggest that D374Y-PCSK9 results in up-regulation of genes involved in sterol biosynthesis and down-regulation of stress-response genes and specific inflammation pathways. (c) 2008 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18570182     DOI: 10.1002/jcp.21519

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  16 in total

Review 1.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

2.  PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.

Authors:  Ming-Xue Piao; Ji-Wei Bai; Peng-Fei Zhang; Ya-Zhuo Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.

Authors:  Yashashwi Pokharel; Salim S Virani; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

4.  PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.

Authors:  Kai Kysenius; Pranuthi Muggalla; Kert Mätlik; Urmas Arumäe; Henri J Huttunen
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

5.  PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways.

Authors:  Xiaohui Xu; Yushang Cui; Lei Cao; Ye Zhang; Yan Yin; Xue Hu
Journal:  Exp Ther Med       Date:  2017-03-10       Impact factor: 2.447

Review 6.  Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.

Authors:  Mariana Pehar; Luigi Puglielli
Journal:  Biochim Biophys Acta       Date:  2012-12-13

Review 7.  PCSK9 Inhibitors: potential in cardiovascular therapeutics.

Authors:  Rose Q Do; Robert A Vogel; Gregory G Schwartz
Journal:  Curr Cardiol Rep       Date:  2013-03       Impact factor: 2.931

Review 8.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

9.  Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.

Authors:  Xiaowei Sun; Rachid Essalmani; Robert Day; Abdel M Khatib; Nabil G Seidah; Annik Prat
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

10.  The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review).

Authors:  Qi Wu; Zhi-Han Tang; Juan Peng; Ling Liao; Li-Hong Pan; Chun-Yan Wu; Zhi-Sheng Jiang; Gui-Xue Wang; Lu-Shan Liu
Journal:  Biomed Rep       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.